天目药业(600671) - 2025 Q2 - 季度业绩预告(更正)

Current Period Performance Forecast The company forecasts a return to profitability in H1 2025, with net profit attributable to parent shareholders projected from RMB 8.5 million to RMB 10.5 million 2025 Semi-Annual Performance Forecast | Indicator | Estimated Amount (RMB) | Compared to Same Period Last Year | | :--- | :--- | :--- | | Net Profit Attributable to Parent | RMB 8.5 million - RMB 10.5 million | Expected Increase of RMB 27.0007 million - RMB 29.0007 million | | Net Profit After Non-recurring Items | RMB 4.1 million - RMB 6.1 million | Not Applicable | - The company expects to turn losses into profits in the first half of 2025[4] - This performance forecast has not been audited by a certified public accountant[3] Prior Period Operating Performance In the prior period of 2024, the company reported a net loss attributable to parent company shareholders of RMB 18.5007 million 2024 Semi-Annual Performance Review | Indicator | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Parent | RMB -18.5007 million | | Net Profit After Non-recurring Items | RMB -22.0571 million | | Earnings Per Share | RMB -0.1519 | Primary Reasons for Performance Pre-profit Return to profitability is primarily driven by enhanced terminal sales across pharmaceutical, health product, and medical device segments - The primary driver of performance growth is the company's continued focus on core strengths, strengthening the layout and terminal sales of pharmaceutical, health product, and medical device segments[7] - These measures led to a significant year-on-year increase in the company's product sales volume and revenue, improving overall profitability[7] Risk Warning and Other Explanations This performance forecast is a preliminary, unaudited estimate, with final data subject to the official 2025 semi-annual report - This performance forecast is a preliminary estimate by the company's finance department based on its professional judgment and has not yet been audited by a certified public accountant[8] - The company states that there are no significant uncertainties affecting the accuracy of this performance forecast[8] - The final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to be aware of investment risks[9]